BNC210, Emerging Drug Insight and Market Forecast - 2032

“BNC210, Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about BNC210 for Post-traumatic Stress Disorder in seven major markets. A detailed picture of the BNC210 for Post-traumatic Stress Disorder in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the BNC210 for Post-traumatic Stress Disorder. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BNC210 market forecast analysis for Post-traumatic Stress Disorder in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Post-traumatic Stress Disorder.

Drug Summary

BNC210 is Bionomics' proprietary molecule in development for the treatment of Social Anxiety Disorder (SAD), Post-traumatic Stress Disorder), and anxiety disorders. As a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR), it has a novel mechanism of action, and extensive non-clinical and clinical studies have shown it has several properties which may be useful to treat Post-traumatic Stress Disorder, SAD, and anxiety disorders. A Phase 2 clinical trial to evaluate BNC210 for acute treatment of Social Anxiety Disorder (SAD), referred to as the PREVAIL Study, is underway and the topline data are expected by the end of 2022. The PREVAIL Study is a randomized, double-blind, placebo-controlled trial to evaluate the tablet formulation of BNC210 on anxiety levels in patients with SAD during an anxiety-provoking behavioral task approximately one hour after receiving a single dose of study medication. The primary and secondary endpoints of the study will compare BNC210 to placebo on self-reported anxiety levels in anticipation of, and during the behavioral task, as well as evaluate the safety and tolerability of BNC210 in this population.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the BNC210 description, mechanism of action, dosage and administration, research and development activities in Post-traumatic Stress Disorder.
• Elaborated details on BNC210 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the BNC210 research and development activities in Post-traumatic Stress Disorder across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around BNC210.
• The report contains forecasted sales of BNC210 for post-traumatic stress disorder till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Post-traumatic Stress Disorder.
• The report also features the SWOT analysis with analyst views for BNC210 in Post-traumatic Stress Disorder.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BNC210 Analytical Perspective

In-depth BNC210 Market Assessment

This report provides a detailed market assessment of BNC210 for post-traumatic stress disorder in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

BNC210 Clinical Assessment

The report provides the clinical trials information of BNC210 for Post-traumatic Stress Disorder covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for post-traumatic stress disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence BNC210 dominance.
• Other emerging products for Post-traumatic Stress Disorder are expected to give tough market competition to BNC210 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of BNC210 in Post-traumatic Stress Disorder.
• Our in-depth analysis of the forecasted sales data of BNC210 from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BNC210 in Post-traumatic Stress Disorder.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of BNC210?
• What is the clinical trial status of the study related to BNC210 in post-traumatic stress disorder and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BNC210 development?
• What are the key designations that have been granted to BNC210 for Post-traumatic Stress Disorder?
• What is the forecasted market scenario of BNC210 for Post-traumatic Stress Disorder?
• What are the forecasted sales of BNC210 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to BNC210 for Post-traumatic Stress Disorder?
• Which are the late-stage emerging therapies under development for the treatment of Post-traumatic Stress Disorder?